- Home
- KRNY vs KROS Comparison
KRNY vs KROS Comparison
Compare KRNY & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRNY
- KROS
- Stock Information
- Founded
- KRNY 1884
- KROS 2015
- Country
- KRNY United States
- KROS United States
- Employees
- KRNY N/A
- KROS N/A
- Industry
- KRNY Savings Institutions
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- KRNY Finance
- KROS Health Care
- Exchange
- KRNY Nasdaq
- KROS Nasdaq
- Market Cap
- KRNY 450.4M
- KROS 465.2M
- IPO Year
- KRNY 2005
- KROS 2020
- Fundamental
- Price
- KRNY $6.35
- KROS $10.04
- Analyst Decision
- KRNY Buy
- KROS Buy
- Analyst Count
- KRNY 2
- KROS 12
- Target Price
- KRNY $7.75
- KROS $27.86
- AVG Volume (30 Days)
- KRNY 322.5K
- KROS 708.7K
- Earning Date
- KRNY 04-24-2025
- KROS 05-07-2025
- Dividend Yield
- KRNY 7.03%
- KROS N/A
- EPS Growth
- KRNY N/A
- KROS N/A
- EPS
- KRNY N/A
- KROS N/A
- Revenue
- KRNY $148,070,000.00
- KROS $3,550,000.00
- Revenue This Year
- KRNY $2.70
- KROS $65.83
- Revenue Next Year
- KRNY $24.88
- KROS $1.36
- P/E Ratio
- KRNY N/A
- KROS N/A
- Revenue Growth
- KRNY N/A
- KROS 2250.99
- 52 Week Low
- KRNY $5.28
- KROS $9.41
- 52 Week High
- KRNY $8.59
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- KRNY 43.22
- KROS 35.08
- Support Level
- KRNY $6.29
- KROS $11.18
- Resistance Level
- KRNY $6.58
- KROS $11.63
- Average True Range (ATR)
- KRNY 0.16
- KROS 0.42
- MACD
- KRNY 0.01
- KROS -0.09
- Stochastic Oscillator
- KRNY 45.24
- KROS 26.69
About KRNY Kearny Financial Corp
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. It is also heavily into secured and unsecured business and consumer loans. The bank's primary source of income is net interest income.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.